Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
Status:
Terminated
Trial end date:
2018-08-15
Target enrollment:
Participant gender:
Summary
The purpose of the Phase 1b dose finding phase is to determine the safety, tolerability, and
maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of TAK-659 in participants with
relapsed or refractory AML. The purpose of the Phase 2 expansion phase is to evaluate
preliminary efficacy of TAK-659 in relapsed or refractory AML as measured by overall response
rate (ORR).